HealthCare Royalty Partners
Latest From HealthCare Royalty Partners
Genentech pays $30m up front in a collaboration with Bicycle in a deal that could bring the UK biotech roughly $1.7bn in total. Also, deals involving Nimble, Seattle Genetics, Five Prime, Fresenius, Vifor, Yuhan, Imnewrun, Paratek, Almirall, MBD, AzothBio, Norgine, Faes, Aspen Pharmacare, Swixx.
Financings Of The Fortnight: In The Aftermath Of Facebook IPO, Kythera Steps Up, TVAX And Cancer Genetics Back Off
Plus news on recent financing activity by TVM Capital, Royalty Pharma, Prosonix and Sangart.
Plus news on recent financings by Warp Drive Bio, Synageva BioPharma, Elevation Pharmaceuticals and Acceleron Pharma.
Two veteran life-science venture firms are pushing forward with new funds even as many of their peers can't persuade backers to open their wallets.